Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia

Schizophrenia Research

Volumn 35, Issue SUPPL., 1999, Pages

  Revicki, Dennis A ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Antipsychotic drugs; Clozapine; Olanzapine; Pharmacoeconomic studies; Risperidone

Indexed keywords

CLOZAPINE; FLUPHENAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG COST; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COST-BENEFIT ANALYSIS; HUMANS; PIRENZEPINE; RESEARCH DESIGN; RISPERIDONE; SCHIZOPHRENIA;

EID: 0033106328     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00168-6     Document Type: Conference Paper

References (30)

1. Addington D.E., Jones B., Bloom D., Chouinard G., Remington G., Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin. Ther. 15:1993;917-926.
2. Awad A.G., Voruganti L.N.P., Heslegrave R.J. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics. 11:1997;32-47.
3. Conley, R.L., Love, R.C., Kelly, D.L., Bartko, J., 1997. Rehospitalized rate of recently discharged patients treated with risperidone. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology, Kanuela, HI, December.
4. Daniel D.G., Whitcomb S.R. Treatment of the refractory schizophrenic patient. J. Clin. Psychiatry. 59(Suppl. 1):1998;13-21.
5. Davies L.M., Drummond M.F. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br. J. Psychiatry. 162:1993;38-42.
6. Davies A., Langley P.C., Keks N.A., Catts S.V., Lambert T., Schweitzer I. Risperidone versus haloperidol: II. cost-effectiveness. Clin. Ther. 20:1998;196-213.
7. Dellva M.A., Tran P., Tollefson G.D., Wentley A.L., Beasley C.M. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr. Serv. 48:1997;1571-1577.
8. Drummond, M.F., Stoddart, G., Torrance, G.W., 1987. Methods for the Evaluation of Health Care Programmes. Oxford University Press, Oxford.
9. Essock S.M., Hargreaves W.A., Dohm F.A., Goethe J., Carver L., Hipshman L. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol. Bull. 32:1996;683-697.
10. Frankenburg F.R., Zanarini M.C., Cole J.O., McElroy S.L. Hospitalization rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann. Clin. Psychiatry. 4:1992;247-250.
11. Glazer W., Ereshefsky L. A pharmacoeconomic model of outpatient neuroleptic therapy in 'revolving door' schizophrenic patients. J. Clin. Psychiatry. 57:1996;337-345.
12. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C., 1996. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York.
13. Guest J.F., Hart W.M., Cookson R.F., Lindstrom E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br. J. Medical Econ. 10:1996;59-67.
14. Hamilton, S.H., Revicki, D.A., Genduso, L., Tollefson, G., 1998. Costs of olanzapine treatment compared with haloperidol treatment for schizophrenia: results from a randomized clinical trial. Presented at the 9th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February.
15. Hargreaves W.A., Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J. Clin. Psychiatry. 57(Suppl. 9):1996;66-76.
16. Honigfeld G., Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp. Community Psychiatry. 41:1990;882-885.
17. Mahmoud, R.A., Englehart, L.M., Oster, G., Stevens, M.C., Meredith, C., Lee, D.M., 1997. Risperidone vs. conventional antipsychotics: a prospective randomized naturalistic effectiveness trial of outcomes in chronic schizophrenia. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology, Kanuela, HI, December.
18. Meltzer H., Cola P., Way L., Thompson P.A., Bastani B., Davies M.A., Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry. 150:1993;1630-1638.
19. Oh, P., Einarson, T.R., Iskedjian, M., Lanctot, K., 1997. Pharmacoeconomic evaluation of risperidone and clozapine in chronic and treatment-resistant schizophrenia. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada.
20. Palmer C.S., Revicki D.A., Genduso L.A., Hamilton S.H., Brown R.E. A cost-effectiveness clinical decision model for schizophrenia. Am. J. Managed Care. 4:1998;345-355.
21. Reid W.H., Mason M., Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp. Community Psychiatry. 45:1994;261-264.
22. Revicki D.A., Luce B.R., Weschler J., Brown R.E., Adler M.A. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp. Community Psychiatry. 41:1990;850-854.
23. Revicki, D.A., Brown, R.E., 1992. Clozapine treatment and economic outcomes: a reanalysis based on the mental health services utilization of treatment-resistant schizophrenics. Presented at Clozaril: A National Dialogue, Virginia Department of Mental Health, Mental Retardation, and Substance Abuse Services, Rosslyn, VA, July.
24. Revicki, D.A., Genduso, L., Hamilton, S., Martin, C., Reblando, J., Tran, P., 1996. Quality of life outcomes of olanzapine and haloperidol treatment for schizophrenia and other psychotic disorders. Proceedings of the Annual Meeting of the American Psychiatric Association, Washington, DC, 184-185.
25. Revicki D.A. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J. Psychiatry Neurosci. 22:1997;256-266.
26. Revicki, D.A., 1998. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. J. Clin. Psychiatry, in press.
27. Rosenheck R.A., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N. Engl. J. Med. 337:1997;809-815.
28. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
29. Viale G., Mechling L., Maislin G., Durkin M., Englehart L., Lawrence B.J. Impact of risperidone on the use of mental health care resources. Psychiatr. Serv. 48:1997;1153-1159.
30. Wyatt R.J., Henter I., Leary M.C., Taylor E. An economic evaluation of schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 30:1995;196-205.